Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the ...

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with ...

The rumored Summit-AstraZeneca deal would follow a move by Bristol Myers BMY, which recently signed a similar licensing deal worth $11 billion with BioNTech. Per the deal terms, Bristol Myers and ...